Vonsetamig Biosimilar - Research Grade

Human

CD3E, TNFRSF17

5mg/ml

Human IgG4 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P07766;Q02223

Blue ice

Bispecific engagement of CD3E and TNFRSF17 (BCMA) bridges T cells to plasma-cell antigens and is a leading strategy in multiple myeloma immunology research. This recombinant bispecific antibody is an unconjugated, non-therapeutic analog of vonsetamig, intended for research use only (RUO). Manufactured to rigorous in vivo standards and purified to low endotoxin, it is supplied in scalable milligram (mg) to gram (g) quantities for high-throughput and heavy-usage laboratories. It is suited to T-cell redirection assays, cytotoxicity and in vitro functional screening, and in vivo immuno-oncology models, offering reproducible performance as a research reagent.

Detects human CD3E, TNFRSF17

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

4 weeks